Shanghai OPM Biosciences (688293.SH) is planning a major asset restructuring, and trading will be halted starting tomorrow.

Shanghai OPM Biosciences (688293.SH) announced that the company is planning to acquire the controlling rights of Pengli Biomedical Technology (Shanghai) Co., Ltd. ("Pengli Biomedical") through the issuance of shares and cash payment, while also raising funds. The transaction is expected to constitute a major asset restructuring. The company's stock is scheduled to be suspended from trading starting on January 17, 2025 (Friday), with the suspension expected to last for no more than 5 trading days.